= omni die (every day); PAD = peripheral arterial disease; PCC = prothrombin complex concentrate; PCI = percutaneous coronary intervention; PREVAIL = Prospective Ran- domized Evaluation of the Watchman LAA Closure Device In Pa- tients With Atrial Fibrillation Versus Long Term Warfarin Therapy trial; PROTECT AF = Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation; RCT = ran- domized controlled trial; RE-ALIGN = Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement; RE-LY = Ran- domized Evaluation of Long-term Anticoagulant Therapy with Dabigatran Etexilate; RE-VERSE AD = Reversal Effects of Idar- ucizumab on Active Dabigatran; ROCKET AF = Rivaroxaban Once daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; RR = risk ratio; SPAF-I = Stroke Prevention in AF; TEE = transesophageal echocardiography; TIA = transient ischemic attack; t.i.d. = ter in die (three times daily); TT = thrombin time; TTE = transthoracic echocardiography; TTR = time in therapeutic range; UFH = unfractionated heparin; VKA = vitamin K antagonist AFFILIATIONS: From the Institute of Cardiovascular Sciences, Uni- versity of Birmingham, United Kingdom; Liverpool Centre for Car- diovascular Science, University of Liverpool, and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (Dr Lip); Institute of Health Informatics, [ Evidence-Based Medicine ] (female)] score of 0 in males or 1 in females), we suggest no antithrombotic therapy. The next step is to consider stroke prevention (ie, oral anticoagulation therapy) for patients with 1 or more non-sex CHA2DS2-VASc stroke risk factors. 